No quarterly revenue total was found in MOONLAKE IMMUNOTHERAPEUTICS's SEC filings.
Moonlake Immunotherapeutics (MLTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$63.4 million. As of Sep 30, 2026 it held $498.5 million in cash and investments and $101.6 million in total debt.
Revenue
—
Net income
$-79.55M
-14.1% vs year-ago quarter
Operating cash flow
$-63.40M
-42.3% vs year-ago quarter
Free cash flow
$-63.40M
-42.3% vs year-ago quarter
EPS
$-0.93
+15.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
85.11M
+0.0% vs prior quarter
Net cash
$396.85M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$79.9M | -$61.7M | -$70.0M | -$65.2M | -$71.4M |
| Net income | -$79.5M | -$61.8M | -$69.7M | -$62.4M | -$69.7M |
| Diluted EPS | -$0.93 | -$0.84 | -$0.98 | -$0.92 | -$1.10 |
| Operating cash flow | -$63.4M | -$55.6M | -$66.3M | -$58.8M | -$44.5M |
| Free cash flow | -$63.4M | -$55.6M | -$66.3M | -$58.8M | -$44.5M |
| Total assets | $540.7M | $573.9M | $400.4M | $424.4M | $414.3M |
| Total liabilities | $159.1M | $145.8M | $146.3M | $120.0M | $123.1M |
| Stockholders' equity | $381.6M | $428.2M | $254.0M | $304.5M | $288.9M |
| Cash and investments | $498.5M | $537.0M | $357.9M | $394.0M | $380.5M |
| Total debt | $101.6M | $101.5M | $100.8M | $75.7M | $75.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
All 331 Moonlake Immunotherapeutics SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.